Despite modern practices, heart failure remains an important cause of morbidity and mortality worldwide. The overarching goal of our laboratory is to identify disease mechanisms that contribute to the pathogenesis of heart failure and design novel strategies to effectively treat these important diseases. To tackle these challenging issues we have focused our efforts on two poorly understood areas with limited available therapies.

 

Precision Therapies for Heart Failure

For patients with dilated cardiomyopathies, little is known regarding precise mechanisms by which genetic variants result in heart failure and by what extent these mechanisms may vary between different genetic etiologies. To approach this problem and define precision therapeutics for dilated cardiomyopathy, we utilize Zebrafish and Mouse models in conjunction with advanced imaging and high throughput chemical screening platforms. 

 

Immune Cell Heterogeneity and Ontogeny

Independent of the cause of heart failure (ischemic or non-ischemic), once patients develop heart failure, the majority of individuals will experience disease progression and eventually progress to end-stage disease. However, a small number of patients will experience disease remission and may spontaneously recover cardiac function. While these observations suggest that it is possible to recover a failing heart, surprisingly little is known regarding why individual patients display these divergent responses to cardiac injury. To define the mechanisms that dictate whether a patient will experience disease progression or recover from heart failure, we have focused on understanding how the innate immune system influences the heart’s response to acute and chronic tissue injury. Through these studies we have discovered that the heart contains a diverse and heterogeneous complement of immune cells derived from divergent embryonic origins with unique reparative and inflammatory functions. Current projects in the laboratory are focused on understanding the exact origins of these cells in the mouse and human heart, identifying molecular determinants of cell fate, and deciphering mechanisms by which each cell type is mobilized, activated and mediates its effector functions during development, disease, and regeneration.

Kory Lavine MD, PhD

Immunology Retreat
Pere Marquette Lodge-Grafton
10.12.2017-10.13.2017
6th Annual Cardiovascular Research Day
11.30.2017

UPCOMING EVENTS AND ANNOUNCEMENTS

Graduate Student and Postdoctoral Fellow Positions Available
07.07.2017 

Multidimensional CT images of a mouse model of dilated cardiomyopathy demonstrating chamber enlargement and fiber reorganization.

Zebrafish heart (cmlc::gfp) beating in real time. 120 hours post fertilization. We use Zebrafish as genetic models of dilated cardiomyopathy.

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey

© 2023 by Scientist Personal. Proudly created with Wix.com

This site was designed with the
.com
website builder. Create your website today.
Start Now